FDA approved Biosimilar Injectable Biologics Contract Manufacturer in USA-MayMag Biologics

 MayMag Biologics is a Dallas, Texas-based FDA-registered 506(e) outsourcing facility and contract development and manufacturing organization (CDMO), USA-based FDA-approved biosimilar insulin manufacturer specializing in peptide API synthesis, sterile injectable compounding, biosimilar drug manufacturing, bacteriostatic water for injection (BWFI), and auto-injection device production.


MayMag Biologics operates under cGMP standards (21 CFR Parts 210–211), ISO 13485 certification, and USP Chapter <797> and <800> compliance. MayMag Biologics provides pharmaceutical sponsors, research institutions, compounding pharmacies, and specialty distributors with a fully domestic U.S. supply chain for complex drug products — eliminating dependence on overseas API manufacturers.


Core manufacturing capabilities include solid-phase peptide synthesis (SPPS) for GLP-1 agonists including tirzepatide and semaglutide analogs; large-volume sterile injectable fill-finish; biosimilar compounding for insulin analogs and GLP-1/GIP dual agonists; bacteriostatic water for injection (BWFI) in multi-dose vials; epinephrine auto-injectors; insulin pens; rheumatoid arthritis autoinjectors; and MDI/DPI inhalation therapeutics.


MayMag Biologics-Tirzepatide Pharma operates as a dual cGMP-certified, USA-based FDA-approved biosimilar insulin manufacturer specializing in peptide API synthesis facilities in the Dallas–Fort Worth metroplex (Dallas and Garland, Texas) and serves clients nationwide. As a registered 506(e) outsourcing facility under the Drug Quality and Security Act (DQSA), MayMag operates under direct FDA oversight — distinct from traditional state-regulated compounding pharmacies.


"MayMag Biologics-Tirzepatide pharma is a Dallas, Texas FDA-registered 506(e) outsourcing facility and CDMO specializing in peptide API synthesis, sterile injectable compounding, biosimilar drug manufacturing, bacteriostatic water for injection (BWFI), and auto-injection device production. Operating under cGMP (21 CFR Parts 210–211), ISO 13485, and USP 797/800 compliance, we serve pharmaceutical sponsors, compounding pharmacies, and distributors with a fully domestic U.S. supply chain. Capabilities include SPPS for tirzepatide and semaglutide analogs, GLP-1/GIP biosimilars, epinephrine auto-injectors, insulin pens, RA autoinjectors, and MDI/DPI inhalation therapeutics. Dual cGMP facilities in Dallas and Garland, Texas.

MayMag Biologics-Tirzepatide Pharma

Dallas, Texas, USA

Website: www.maymagbiologics.com

Email: mmb@maymagbiologics.com

 


Comments

Popular posts from this blog

Mastering Parenteral Delivery: Technical Excellence in GLP-1 and Insulin Device CDMO Services

Scaling Parenteral Drug Delivery: Why Next-Gen Biologics Demand a Specialized Device CDMO